GSK
Glaxosmithkline plc - ADR

9,487
Mkt Cap
$71.05B
Volume
5.57M
52W High
$46.87
52W Low
$31.72
PE Ratio
20.96
GSK Fundamentals
Price
$43.14
Prev Close
$45.54
Open
$43.76
50D MA
$41.44
Beta
0.26
Avg. Volume
4.5M
EPS (Annual)
$1.61
P/B
4.55
Rev/Employee
$584,193.84
Loading...
Loading...
News
all
press releases
Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma
GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone (BVd) for the...
Business Wire·17h ago
News Placeholder
More News
News Placeholder
Illumina (ILMN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·1d ago
News Placeholder
Top Analyst Reports for Oracle, Toyota & Morgan Stanley
Oracle gains from cloud momentum and AI contracts, Toyota drives hybrid and hydrogen growth, while Morgan Stanley thrives on IB strength.
Zacks·2d ago
News Placeholder
GSK (GSK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Glaxo (GSK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·2d ago
News Placeholder
Here's Why GSK (GSK) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks·3d ago
News Placeholder
Here's Why GSK (GSK) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks·4d ago
News Placeholder
Will Positive Regulatory Updates Further Boost INCY Stock?
Incyte's strong 2025 performance is fueled by Jakafi's sustained growth and label expansion of Opzelura.
Zacks·4d ago
News Placeholder
Will Livmarli Continue to Drive Mirum's Top Line in Q3 Earnings?
MIRM's Livmarli remains its dominant growth engine and is expected to have boosted its top line in the third quarter.
Zacks·10d ago
News Placeholder
Why GSK (GSK) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks·15d ago
News Placeholder
Gilead Resolves Patent Litigations for HIV Treatment Biktarvy
Gilead's settlement on Biktarvy patents delays generic entry until 2036, boosting investor confidence.
Zacks·17d ago

Latest GSK News

View

Advertisement|Remove ads.

Advertisement|Remove ads.